23 results
8-K
EX-99.1
ADPT
Adaptive Biotechnologies Corp
5 Apr 24
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
4:30pm
the full value of both MRD and Immune Medicine businesses. I would like to thank Tycho for his financial leadership and significant contributions … to Adaptive over the past two years, including his leadership during the strategic review process. We wish him success in his next endeavor.”
“I’m proud
8-K
EX-99.1
ADPT
Adaptive Biotechnologies Corp
9 May 23
Regulation FD Disclosure
7:38am
for the treatment of a broad range of cancers. The collaboration combines Genentech’s global cancer immunotherapy research and development leadership
8-K
EX-99.1
ngiskg
4 May 22
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
4:12pm
DEF 14A
exuojh9p hwgqafd
24 Apr 20
Definitive proxy
4:15pm
10-K
fyuo8ogmj6sczq8p5zj
26 Feb 20
Annual report
4:53pm
424B4
ybi0dla4h bl5v
24 Jan 20
Prospectus supplement with pricing info
4:49pm
DRS
tywq7818uo67
9 Jan 20
Draft registration statement
12:00am
8-K
EX-10.2
nmm1wn3u74uhrqd4nst
7 Aug 19
Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub
5:29pm
424B4
s9kr3acq
27 Jun 19
Prospectus supplement with pricing info
5:24pm